BOLERO-2
BOLERO-2 showed that adding the mTOR inhibitor everolimus to the hormone drug exemestane more than doubled the time that advanced breast cancer stayed under control after aromatase inhibitors had stopped working, the first targeted drug to overcome endocrine resistance.
Overview
BOLERO-2 randomised 724 postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer that had recurred or progressed on letrozole or anastrozole two to one to exemestane plus everolimus or exemestane plus placebo. The primary endpoint was progression-free survival.
Everolimus more than doubled median progression-free survival, at the cost of stomatitis, rash, fatigue, hyperglycaemia and pneumonitis, and overall survival was not significantly different. It was approved in the United States in July 2012 and was the standard second-line option until CDK4/6 inhibitors arrived; it remains an option after CDK4/6 inhibitor progression, particularly in tumours without a PIK3CA mutation.
Similar pages
not linked directly; found by shared links- TrialPENELOPE-B
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag subtype-trials.
- TrialPATINA
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag subtype-trials.
- TrialCheckMate 025
Shares Everolimus and the tag subtype-trials.
- TrialTAM-01
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialCOMET (Comparison of Operative versus Monitoring and Endocrine Therapy)
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialATEMPT
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialTUXEDO-1
Shares Breast cancer (all types) and the tag subtype-trials.
- TrialGeparSixto
Shares Breast cancer (all types) and the tag subtype-trials.